Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- DIAGNOSTIC NEWS IN BRIEF
March 18, 2002
- OTC NEWS IN BRIEF
March 18, 2002
- Pharmacies Concerned about Effects of Revision of Medical Fees: Survey
March 18, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
March 18, 2002
- Importance of Training Rheumatologists Stressed: RDIC Seminar
March 18, 2002
- Nippon Roche to Participate in Multinational Study on Herceptin: JSMO Meeting
March 18, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
March 18, 2002
- REGULATORY NEWS IN BRIEF
March 18, 2002
- Committee to Propose Intellectual Property Strategy by Summer
March 18, 2002
- New NHI Prices to Be Effective on April 1
March 18, 2002
- Pravastatin Is Beneficial for Postmenopausal Hyperlipidemia: Seminar
March 18, 2002
- Korosho's PAL Amendment Bill Approved by LDP
March 18, 2002
- Evidence-Based Infection Control GL Established
March 18, 2002
- Sales of Bonalon Remain at 60% of Target
March 18, 2002
- ICH Meeting in Brussels Reported by Korosho
March 18, 2002
- Eisai Aims at Sales of \550 Bil. in FY2006: President Naito
March 18, 2002
- Reform Must Be Carried Out at Any Cost: Health Minister
March 18, 2002
- GE Maker Lost the Game: Mr Sawai
March 11, 2002
- Hokuriku: Sales Increase by 22% to \24.9 Bil.
March 11, 2002
- New SMO Industry Organization to Be Created in April
March 11, 2002
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…